The drug laquinimod reduced the number of relapses for people with multiple sclerosis (MS) in a large, long-term Phase III clinical study that will be presented as late-breaking research at the 63rd Annual Meeting of the American Academy of Neurology in Honolulu, Hawaii.
Recent Comments